Prognostic impact of unsupervised early assessment of bulk and leukemic stem cell measurable residual disease in acute myeloid leukemia.

Alban Canali Inès Vergnolle Sarah Bertoli Laëtitia Largeaud Marie-Laure Nicolau Jean Baptiste Rieu Suzanne Tavitian Françoise Huguet Muriel Picard Pierre Bories Jean-Philippe Vial Nicolas Lechevalier Marie Christine Bene Isabelle Luquet Véronique De Mas Eric Delabesse Christian Recher François Vergez

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

In this study, we confirm the prognostic impact of post-induction MFC Bulk MRD in AML patients. Focusing on LSCs, we identified a group of patients with negative Bulk MRD but positive LSC MRD (25.8% of our cohort) with an intermediate prognosis, demonstrating the interest of MRD analysis focusing on leukemic chemoresistant subpopulations.

Keyphrases

acute myeloid leukemia
stem cells
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
machine learning
peritoneal dialysis
mesenchymal stem cells
allogeneic hematopoietic stem cell transplantation
acute lymphoblastic leukemia
cell therapy